SOLB Stock Analysis: Solvay | BR
Chemicals | BR, Belgium | Market Cap: 2.819m EUR | 12M Return: 5.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.40M
EPS Trend: -91.6%
Qual. Beats: 2
Rev. Trend: -87.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Solvay SA is a Belgian diversified chemicals producer that manufactures both basic and performance chemicals for global markets, organized under the Materials sector. The companys product portfolio spans soda ash and derivatives (used in glass, lithium-ion batteries, and detergents), sodium bicarbonate (for food, feed, and healthcare), hydrogen peroxide (for pulp, paper, water treatment, and electronics), precipitated and highly dispersible silica (primarily for tires and personal care), polyamides, oxygenated solvents, and fluorine and rare-earth formulations for automotive and electronics applications.
The business model is anchored in serving industrial B2B customers across multiple end-markets, including construction, automotive, packaging, food production, and electronics, with a portfolio mix of commodity-scale basic chemicals and higher-value specialty products. Founded in 1863 and headquartered in Brussels, Solvay has built its position through long-standing process expertise, particularly in soda ash and hydrogen peroxide production, and supplies both downstream manufacturers and intermediate chemical processors worldwide.
- Soda ash segment drives revenue on solar glass and battery demand
- European energy costs compress soda ash and peroxide margins
- Tire silica volumes track global automotive production
| Net Income: 3.00m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 2.28 > 1.0 |
| NWC/Revenue: 5.84% < 20% (prev 10.60%; Δ -4.76% < -1%) |
| CFO/TA 0.09 > 3% & CFO 576.0m > Net Income 3.00m |
| Net Debt (2.24b) to EBITDA (673.0m): 3.33 < 3 |
| Current Ratio: 1.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.5m) vs 12m ago -0.02% < -2% |
| Gross Margin: 21.39% > 18% (prev 21.23%; Δ 0.16% > 0.5%) |
| Asset Turnover: 73.92% > 50% (prev 78.69%; Δ -4.77% > 0%) |
| Interest Coverage Ratio: 2.44 > 6 (EBIT TTM 286.0m / Interest Expense TTM 117.0m) |
| A: 0.04 (Total Current Assets 2.05b - Total Current Liabilities 1.78b) / Total Assets 6.08b |
| B: 0.23 (Retained Earnings 1.40b / Total Assets 6.08b) |
| C: 0.05 (EBIT TTM 286.0m / Avg Total Assets 6.19b) |
| D: 0.21 (Book Value of Equity 1.04b / Total Liabilities 4.96b) |
| Altman-Z'' = 1.57 = BB |
| DSRI: 0.99 (Receivables 1.04b/1.14b, Revenue 4.57b/4.96b) |
| GMI: 0.99 (GM 21.23% / 21.39%) |
| AQI: 1.01 (AQ_t 0.28 / AQ_t-1 0.28) |
| SGI: 0.92 (Revenue 4.57b / 4.96b) |
| TATA: -0.09 (NI 3.00m - CFO 576.0m) / TA 6.08b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of August 02, 2026, the stock is trading at EUR 26.56 with a total of 377,425 shares traded. Over the past week, the price has changed by +0.53%, over one month by +1.07%, over three months by +0.81% and over the past year by +5.76%.
Current recommended Stop Loss: 25.10 (which is 5.5% or 2.3 ATR below the current price).
Solvay has no consensus analysts rating.
P/E Trailing = 899.3333
P/E Forward = 11.0988
P/S = 0.6068
P/B = 2.6734
P/EG = 0.2896
Revenue TTM = 4.57b EUR
EBIT TTM = 286.0m EUR
EBITDA TTM = 673.0m EUR
Long Term Debt = 1.82b EUR (from longTermDebt, last quarter)
Short Term Debt = 417.0m EUR (from shortTermDebt, last quarter)
Debt = 2.62b EUR (from shortLongTermDebtTotal, last quarter) + Leases 379.0m
Net Debt = 2.24b EUR (calculated: Debt 2.62b - CCE 376.0m)
Enterprise Value = 5.06b EUR (2.82b + Debt 2.62b - CCE 376.0m)
Interest Coverage Ratio = 2.44 (Ebit TTM 286.0m / Interest Expense TTM 117.0m)
EV/FCF = 13.56x (Enterprise Value 5.06b / FCF TTM 373.0m)
FCF Yield = 7.37% (FCF TTM 373.0m / Enterprise Value 5.06b)
FCF Margin = 8.16% (FCF TTM 373.0m / Revenue TTM 4.57b)
Net Margin = 0.07% (Net Income TTM 3.00m / Revenue TTM 4.57b)
Gross Margin = 21.39% ((Revenue TTM 4.57b - Cost of Revenue TTM 3.60b) / Revenue TTM)
Gross Margin QoQ = 18.67% (prev 23.29%)
Tobins Q-Ratio = 0.83 (Enterprise Value 5.06b / Total Assets 6.08b)
Interest Expense / Debt = 4.47% (Interest Expense 117.0m / Debt 2.62b)
Taxrate = 0.0% (0.0 / 40.0m)
NOPAT = 286.0m (EBIT 286.0m * (1 - 0.00%))
Current Ratio = 1.15 (Total Current Assets 2.05b / Total Current Liabilities 1.78b)
Debt / Equity = 2.50 (Debt 2.62b / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = 3.33 (Net Debt 2.24b / EBITDA 673.0m)
Debt / FCF = 6.00 (Net Debt 2.24b / FCF TTM 373.0m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.05% (Net Income 3.00m / Total Assets 6.08b)
RoE = 0.27% (Net Income TTM 3.00m / Total Stockholder Equity 1.10b)
RoCE = 9.81% (EBIT 286.0m / Capital Employed (Equity 1.10b + L.T.Debt 1.82b))
RoIC = 6.38% (NOPAT 286.0m / Invested Capital 4.48b)
WACC = 5.08% (E(2.82b)/V(5.43b) * Re(5.65%) + D(2.62b)/V(5.43b) * Rd(4.47%) * (1-Tc(0.0)))
Discount Rate = 5.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.92 | Cagr: -0.28%
[DCF] Terminal Value 77.97% ; FCFF base≈321.0m ; Y1≈368.0m ; Y5≈541.6m
[DCF] Fair Price = 56.57 (EV 8.15b - Net Debt 2.24b = Equity 5.91b / Shares 104.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -91.55 | EPS CAGR: -46.23% | SUE: 1.21 | # QB: 2
Revenue Correlation: -87.42 | Revenue CAGR: -31.39% | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.41 | Chg30d=-12.77% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=2.31 | Chg30d=-0.09% | Revisions=-12% | GrowthEPS=-18.8% | GrowthRev=-3.6%
EPS next Year (2027-12-31): EPS=2.57 | Chg30d=-1.14% | Revisions=-22% | GrowthEPS=+11.6% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: -13% (up=5, down=7)